Major histocompatibility complex (MHC) class II deficiency is an inherited autosomal recessive combined immunodeficiency. The disease is known as bare lymphocyte syndrome (BLS). BLS is characterized by a lack of constitutive MHC class II expression on macrophages and B cells as well as a lack of induced MHC class II expression on cells other than professional antigenpresenting cells (APCs) due to the absence of mRNA and protein of the human leukocyte antigen (HLA) class II molecules, designated HLA-DR, -DO~ and -DP. The defect in gene expression is located at the transcriptional level and affects all class II genes simultaneously. Here we have analyzed transcription and protein expression of class II antigens in Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines and mononuclear cells (MNCs) of twin brothers. Whereas flow cytometric analysis failed to detect class II antigens on the cell surface of the patients' EBV-B cells and MNCs, examination of the genes coding for HLA-DR, -DQ, -DP, and the invariant chain (Ii) by reverse transcriptase-polymerase chain reaction amplification resulted in an unusual mRNA pattern in the B cell lines of the patients (HLA-DRa § -DtLS-, -DQo~ +, -DQ~-, -DPol-, -DP~ +, Ii+). In accordance with these findings no HLA-DRB-specific protein was detected by immunoblotting, whereas low levels of HLA-DRo~ and normal levels of Ii were present. In contrast to EBV-B cells, the MNCs of both patients displayed a residual HLA-DILS, -DOff, and -DPol mRNA signal. Furthermore, HLA-DRB-specific protein was found in addition to HLA-DRc~ by immunoblotting of cell lysates, even though it was dearly decreased as compared with controls. Our results indicate that the defect in class II antigen expression is not necessarily present to the same extent in B cells and cells of other lineages, mRNA levels of HLA-DtL8 were found to be enriched in adherent cells within the MNC fraction. Further investigations indicated that the MHC class II expressed is functional in antigen presentation, as the two boys' CD4 + T cells became activated and expressed interleukin-2R after stimulation of peripheral blood mononuclear cell cultures with recall antigen (tetanus toxoid). Furthermore, T cells tested in one of the two patients responded to both MHC class I and II allostimulation, and this response was inhibited by monoclonal antibodies of the respective specificity. Whereas the MNC population contained sufficient APCs to activate CD4 + T cells in response to antigenic stimulation, the patients' EBV-B cells were unable to present recall antigen to autologous, long-term cultured, antigen-reactive T cells or to a normal, HLA-DR-compatible, antigen-specific T cell line. In contrast, the patients' EBV-B cells functioned normally as accessory cells for mitogen-induced T cell proliferation. The results obtained from the investigations of MHC class II-dependent immune functions indicate antigen presentation by a subset of cells, obviously present in the HLA-DtL8 mRNA-expressing adherent MNC population, whereas the patients' EBV-B cells lack this ability.
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M
HC class II proteins expressed on APCs play a critical role in cellular recognition, in antigen presentation, and in the induction of the immune response. In general, many different peptides derived from naturally processed antigens bind to class II proteins and are then presented to helper T lymphocytes. MHC class II proteins are the product of immune response genes located on the short arm of chromosome 6 of the human genome (1) . The class II locus (HLA-D) is divided into three major subregions designated HLA-DR, -DQ, and -DP (2) , and each isotype is encoded by separate ot and/~ chain genes. Conserved upstream sequence elements, termed W, X, and Y, and proteins that interact with these boxes, have been shown to mediate B cell-specific and IFN-3,-induced expression of several HLA-D locus genes (3, 4) . The HLA-D locus is unusual in that both chains of the various heterodimeric proteins are products of the same genetic region (1) . Before being expressed on the cell surface, all MHC class II proteins are associated with the invariant chain (Ii) 1, and it has been proposed that this chain may direct class II proteins into the endocytic pathway, where they encounter internalized antigens (5) . The level of cell surface expression of class II proteins correlates closely with the level of intracellular class II mRNA (3). Thus, modulation of MHC class II surface expression is generally achieved by regulation of class II gene expression. Impaired expression of the HLA-D locus genes leads to a disease described as bare lymphocyte syndrome (BLS) (6) .
A number of studies have indicated that the HLA-D locus genes and their rearrangement are intact in reported MHC class II-deficient patients and that regulatory mutations are responsible for the lack of stable mRNA (6) (7) (8) . The regulatory mutations involved affect class II expression at the transcriptional level (9). Analysis of MHC class II transcriptional mutant B cell lines that were either derived from BLS patients or produced in vitro has provided a clue to the role of c/s-and tram-acting regulatory factors. Fusion experiments of mutant cell lines to healthy B cell lines resulted in reconstituted expression of all class II genes (3, 10-12). The same experiments carried out between various class II-negative B cell lines have defined four separate complementation groups, suggesting that multiple regulatory defects can cause this disease (3, (10) (11) (12) . The consequences of all regulatory defects are the lack of RNA encoding MHC class II molecules.
In this paper, we present the molecular and immunological characterization of a new phenotype of MHC class II deficiency in twin brothers. Flow cytometric analysis of their mononuclear cells (MNCs) and EBV-B cells isolated and established from peripheral blood of both children failed to detect class II antigen on the cell surface. Therefore, we analyzed transcription and protein expression of MHC class II genes by reverse transcriptase (RT)-PCR and immunoblotting techniques. Our results show an unusual mRNA pattern in the patients' MNCs and EBV-B cells (reduced or undetectable mRNA levels of HLA-DR~, -DQ/3, and -DPc~, and normal mRNA levels encoding HLA-DRol, -DQc~, and -DPB). By fractionating MNCs into nonadherent (lymphoid cell population) and adherent cells (monocyte/macrophage lineage), an enrichment of HLA-DIL/3 gene expression was found in cells of the adherent MNC fraction. Supporting the molecular results, the patients' T cells were capable of responding to recall antigen (tetanus toxoid [Tet Tox]) after 1 Abbreviations used in this paper: BLS, bare lymphocyte syndrome; ~2m, B2-microglobulin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Ii, invariant chain; LF, Loeflter flocculation units; MNC, mononuclear cell; "let Tox, tetanus toxoid.
vaccination. In response to stimulation of the MNCs with recall antigen, in both patients CD4 + and TCR-c~/B § cells were the major lymphocyte phenotype that became activated and expressed IL-2R (CD25). However, patients' EBV-B ceUs were not able to present antigen to autologous, long-term cultured, antigen-reactive T cells or to an HLA-DR-compatible, antigen-specific T cell line from a healthy individual, whereas they functioned normally as accessory cells in the mitogen-response. These results indicate that cells within the monocyte/macrophage lineage, obviously present in the HLA-DRB mRNA-expressing adherent MNC population, are likely to be APCs in these two boys. In comparison to already known class II-deficient cell lines, we describe here a new in vivo phenotype, suggesting the existence of a new complementation group, and provide evidence for the functional equivalent of the molecular characteristics.
Materials and Methods
Patients. The children are histoidentical twin brothers born prematurely at 34 wk of gestation to unrelated healthy parents of Turkish origin. The boys had low birth weight (KEN: 1,020 g, KER: 2,030 g), and were delivered by cesarian section because of premature rupture of membranes. The detailed clinical description of the two boys is reported elsewhere (13). One boy (KEN) was first admitted to the hospital at the age of 10 wk because of febrile seizures, and again with pneumonia at the age of 4 mo. Immunological examination revealed hypogammaglobulinemia, normal lymphoproliferative responses to mitogens, and a normal distribution of lymphocyte subpopulations (CD3 + 62%, CD4 § 43%, CD8 § 23%, and CD19 + 27%). The diagnosis of MHC class II deficiency was based on flow cytometric analysis, which revealed a lack of HLA-DR expression on the patient's resting peripheral blood leukocytes. The other boy (KER) was asymptomatic, and his physical and mental development was uneventful since birth. Immunological studies revealed a defect in MHC class II expression comparable with his twin brother, whereas the distribution of lymphocyte subsets (CD3 § 75%, CD4* 48%, CD8 § 29%, and CD19 § 14%) and the lymphoproliferative responses to mitogens were within the normal range. Serum IgG and IgA levels were normal, but serum IgM was decreased (20 mg/dl).
Isolation of Mononuclear Ceils, Establishment of Lymphoblastoid B Cell Lines and Long-term Cultures ofT Cells. MNCs were isolated from heparinized peripheral blood (7.5 IU/ml) by buoyant density gradient centrifugation (14, 15). After enrichment by multiple rounds of polystyrene adsorption, nonadherent cells were fractionated into T-enriched ceils and non-T cells by rosetting with sheep erythrocytes treated with AET (2-aminoethylisothiouronium bromide; Sigma Chemical Co., St. Louis, MO) as described elsewhere (16) . Non-T cells were transformed with EBV using the supernatant from the B 95-8 marmoset call line (American Type Culture Collection, Rockville, MD) according to a standard protocol (17) . Growing cells were expanded in RPMI 1640 medium supplemented with 20% heat-inactivated FCS (Hyclone Laboratories, Logan, UT), 2 mM t-glutamine, 100 IU/ml penicillin, and 100/~g/ml streptomycin (Gibco, Paisley, Scotland). To establish an antigen-specific T cell line from a healthy, HLA-DR-compatible, control individual or long-term cultured T cells from one (KEN) of the two patients, MNCs from the patient or the control were stimulated with Tet Tox for 1 wk and were then cultured for several weeks in the presence of highly purified human Ib2 (10 IU/ml, Lymphocult T-HPLyo.-Biotest-No.811040, Dreieich, Germany) without (patient) or with (control individual) repeated restimulation using antigen and autologous macrophages. All cell cultures were maintained at 37~ in 5% COs humidified air.
One.way Mixed Lymphocyte Reaction. To examine MHC class I-and II-specific alloresponses in the patient KEN, MNCs from this patient or an unrelated healthy control individual were stimulated for 7 d with irradiated (10,000 tad) Dandi cells or EBVtransformed B cells from another unrelated patient with MHC class II deficiency (BCH). Triplicate cultures of responder cells (2.5 x 10S/ml) and stimulator cells (2.5 x 10S/ml) were set up in flatbottomed microtiter plates (Falcon 3070, Microtest III; Becton Dickinson Labware, Lincoln Park, NJ) in culture medium as previously described (18) Surface expression of the Ib2R on CD3-or CD4-positive cells within the MNC fraction was examined by dual-color flow cytometry after stimulation with antigen or mitogen. Therefore, MNCs (10Vml) were cultured in 24-well tissue culture plates for 7 d in the presence of antigen (Tet Tox, 10 LF/ml), mitogen (PWM, 1:1,000), or culture medium alone. Cells were stained using directly labeled mAbs Leu-4 (CD3), Leu-3a, (CD4), and IL-2R (anti-Tac, CD25) (all purchased from Becton Dickinson & Co., Mountain View, CA) and immunofluorescence staining was evaluated with a cytofluorograph (FACScan | Becton Dickinson & Co.).
Isolation of RNA and Specific Amplification of cDNA. Total cellular RNA was isolated from nonstimulated MNCs and EBVtransformed B calls of the patients (KER, KEN) and healthy controis (HC, MOTHER, FATHER) according to the method of Chomczynski (24) . Equal amounts of total RNA, quantified at 260 nm, were reverse transcribed into cDNA by first and second strand synthesis employing avian myeloblastosis virus (AMV) RT (Boehringer Mannheim Biochemicals, Mannheim, Germany). The cDNA was directly amplified (25, 26) on a thermocycler (model 60; Biomed Instruments Inc., Fullerton, CA) using AmpliTaq DNA polymerase (Perkin Elmer Cetus, Norwalk, CT) and oligonucleotide primer pairs specific for HLA-DRot (exonl, sense: ATGGCC-ATAAGTGGAGTCCCTGTGC; exon4, antisense: CCTGCGTTC-TGCTC~~GCACTCC) (27) , FILA-DRB1 (sense: GTCATTTCTTCAATGGGACGGAGCG, antisense: CGCCGC-TGCACTGTGAAGCTCTC) (28), FILA-DQo~ (KS151 and RS152), HLA-DQB (AmpA and AmpB), HLA-DPtx (AmpA and AmpB) (Genset, Paris, France), HLA-DPB1 (sense: CCTTGCAGCACC-ACAACCTGCTTGTC, antisense: CCTGTGCATGAAGATGCC-CACTCCAC) (29) , HLA-Ii (sense: GGATGACCAGCGCGACCT-TATCTCC, antisense: CCAGATCCTGCTTGGTCACACCCAG) (30), B2m (sense: CTCGCGCTACTCTCTCTTTCTGG, antisense: GCTTACATGTCTCGATCCCACTTAA) (31), TNF-B and M-CSF (Clontech Lab., CA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (sense: CCACCCATGGCAAATTCCATGGCA, antisense: TCTAGACGGCAGGTCAGGTCCACC) (32) , and $14 ribosomal protein (sense: GGCAGACCGAGATGAATCCTCA, antisense: CAGGTCCAGGGGTCTTGGTCC) (33) were used as internal controls. The amplification profile involved 30 cycles (35 cycles for TNF-B and M-CSF) of denaturation at 95~ for 1 min, primer annealing at 60~ for 2 min (Genset primer pairs were annealed at 55~ and primer extension at 72~ for 3 rain. Aliquots of PCR-generated products were fractionated on 1.5% EtBr-agarose gels, validated by the predicted size, and blotted onto Hybond-N filter membranes according to the manufacturer's protocol (Amersham International, Buckinghamshire, UK).
Hybridization and Analysis of Data by Densitometry.
Blotted filter membranes were validated by hybridization with internal probes. Therefore oligonucleotides specific for HLA-DRo~ (exon3: CCT-CAGT1GAGGC~AGGAAGGGGAGATAGTGG) (27) , HLA-DRB1 (CTCCCCCACGTCGCTGTCGAAGCG)(28), HLA-DQcz (exon 2, KI-I54) (Genset), HLA-DQB (CTGGTAGTTGTGTCTGCA-CAC), HLA-DPo~ (Aso: AAGATGAGATGTICTATG or AAGATG-AGCAGTTCTATG) (Genset), HLA-DP~I (CCAGCTCCCGTC-AATGTCTTACTCCG) (29) , HLA-Ii chain (CAGGAGCCAATG-GTGCATCCAGCTCTC) (30), B2m (CACTTTTTCAATTCT-CTCTCCATTCTTCAG) (31) and GAPDH (TCTAGACGGCAG-GTCAGGTCCACC) (32) were 3' end labeled using the enzyme terminal transferase (Boehringer Mannheim Biochemicals) and r 5'-triphosphate (Amersham International). The unincorporated nucleotides were removed on an NAP-5 column (Pharmacia, Uppsala, Sweden). Prehybridization of the filter membranes was carried out for 4 h at the corresponding annealing temperature (55-60~ in 5x SSC, 20 mM NaPO4, pH 7, 10x Denhardt's solution, 7% SDS, 100 #g/ml sonicated salmon sperm DNA, and 100/~g/ml poly(A). Hybridization was performed at 55-60~ in the prehybridization buffer containing 10% dextran sulphate plus added radiolabeled-specific oligonucleotides for 16 h. The blots were washed once in 3x SSC, 20 mM NaPO4 pH 7, 10x Denhardt's solution, 5% SDS for 30 min, followed by a second wash in lx SSC, 1% SDS at hybridization temperature for 40 min. Air-dried filters were exposed to Kodak XDS films using Kodak X-OMATIC regular intensifying screens (Kodak, Rochester, NY).
The relative density of the fragments was determined by imageanalyzing densitometry (OD*MM) (Pharmacia LKB Biotech., pdi Quantity One, Uppsala, Sweden). The densitometric reading of the indicated genes in a particular test was related to the corresponding densitometric reading for the internal controls $14 ribosomal protein and/or GAPDH.
Antibodies. The anti-HLA-class II ~ chain mAbs DA6.147 (34) and 5F2.3 (35) were a generous gift of Dr. C. M. Steel (Western General Hospital, Edinburgh, Scotland) and the anti-HLA-class II t~ chain mAb TAL-1B5 (36) was kindly provided by Dr. J. G. Bodmer (Imperial Cancer Research Fund, Lincoln's Inn Fields, London, UK). The anti-HLA-DIL8 mAb, clone CR3/43, was obtained from Boehringer Mannheim.
Immunoblotting. MNCs were lysed in lx SDS sample buffer and boiled for 5 min before SDS-PAGE. EBV-B cells were lysed in NP-40 lysis buffer (20 mM Tris, pH 7.5, 150 mM NaC1, 1% NP-40, 0.5% deoxycholic acid, I mM PMSF, 10/~g/ml aprotinin, 10 #g/ml leupeptin) and boiled for 5 min in 5 x SDS sample buffer or, alternatively, directly lysed and boiled in lx SDS sample buffer. After electrophoresis, gels were equilibrated in blotting buffer (48 mM Tris, 39 mM glycine, 20% methanol) and proteins were transferred to 0.2 #m nitrocellulose sheets (Schleicher and Schuell, Dassel, Germany) using a Trans-Blot SD semi-dry electrophoretic transfer cell (Bio-Rad Laboratories, Vienna, Austria). The nitrocellulose sheets were blocked in 5% skim milk/TBS (Tris-buffered saline) containing 0.1% Tween-20, and then probed with the primary antibodies. Specific binding was visualized either by autoradiography at -70~ using 3sS-labeled anti-mouse Ig (0.2 #Ci/ml; Amersham International) and Kodak XAR films or with the ECL Western blotting analysis system (Amersham International) in combination with horseradish peroxidase-conjugated anti-mouse Ig (Amersham International) and Kodak XDS films.
Results

Lack of Class II Antigen Expression on EBV-B Cells from
Patients with BLS. Analysis of the patients' EBV-B cells by flow cytometric analysis revealed a lack of MHC class II antigens, whereas Ii chain and class I antigen expression was normal and comparable to a healthy control subject (Fig. 1,  KEN , KER versus HC). Since the mAbs used do not distinguish polymorphism of class II molecules, it is likely that the observed lack of HLA-DR, -DQ, and -DP expression in both children reflected an absence of cell surface class II antigens, each consisting of distinct a and ~/chains (Fig. 1) .
Uncoordinated Expression of el and fl Chain Genes of the HLA-D Region in the Patients.
Having demonstrated the lack of class II antigen on the surface of the MNCs and EBV-B cells (Fig. 1 ) of the patients, we examined class II-specific gene expression. Total RNA from the patients and from three healthy control individuals was subjected to RT-PCR analysis. The PCR-generated products for the genes encoding HLA-DR, -DQ, and -DP c~ and B chains, HLA-associated Ii chain, 32m, and GAPDH were detected by Southern blotting and specific hybridization under conditions in which no cross-hybridization occurs (for details see Materials and Methods). As shown in Fig. 2 , mRNAs encoding DRot, DQc~, and DP/31 clearly accumulated in the MNCs and EBV-B cells of the patients as well as the control subjects. However, no DtL3t-, DQ3-, or DPoe-specific transcripts were seen in the EBV-B ceils, and very low levels could be detected in the MNCs of the patients (Fig. 2, KER and KEN) . were normalized to the expression of the constitutive control mRNA encoding GAPDH. In agreement with the results shown in Fig. 2 , DRBI-, DQ~/-, and DPot-specific mRNA could not be detected in the patients' EBV-B cells, whereas low levels were present in their MNCs (Fig. 3, b, d , and e). Control experiments demonstrated that mRNA expression of the Ii chain (Fig. 3 g) and expression of the B2m gene, which is associated with the class I molecule (Fig. 3 h) , were normal in all individuals tested.
Presence and Distribution of HLA-DR Proteins in Cellular Lysates of Class II-Deficient Patients. To analyze in which way
the defective transcription of one of the chains specific for HLA-DR will affect translation of the observed mRNA (Fig.  2) , we examined the occurrence of intracellular HLA-DR proteins and Ii chain by immunoblotting techniques. As shown in Fig. 4 , despite normal mRNA levels strongly reduced amounts of HLA-DRa protein were found in the cellular lysates of EBV-B cells of both patients, whereas, as was to be expected, no HLA-DRB was detected in the same lysates, even after extensive exposure time. On the other hand, low levels of HLA-DR ot and/3 proteins were observed in the cellular lysates of patients' MNCs (Fig. 4) . In agreement with the results obtained by flow cytometric analysis (Fig. 1) , normal amounts of Ii chain were also found by immunoblotting (data not shown). Amplified products were fractionated on 1.5% agarose gels, blotted onto filter membranes, and hybridized with internal probes (see Materials and Methods). DR oe and 3 proteins were present in MNC lysates, we wanted to identify the cells within the MNC fraction expressing HLA-DR molecules. Therefore, MNCs from one patient (KEN) were divided into nonadherent and adherent cell populations by polystyrene adsorption and the cell lysates were examined by immunoblotting. In good agreement with the results obtained from EBV-B cells, a low level of HLA-DRoe protein was found in the nonadherent cell population, consisting mainly of T and B lymphocytes (Hg. 5). However, HLADRoe strongly accumulated in the adherent cell population (Fig. 5) . Image-analyzing densitometry of the depicted bands revealed a nearly fourfold increase of HLA-DR~ in the adherent cells, reaching 42% of the protein level present in the same cell population of a healthy control. Because of the small number of MNCs available from our patient and the constitutively lower amount of HLA-DRfl present in all cells expressing MHC class II molecules, we were unable to detect HLA-DRfl by immunoblotting in either the nonadherent or the adherent cells. However, the observed increase of HLADRc, protein in the adherent cell population, together with our mRNA data presented in Fig. 6 , strongly suggest that the cells expressing both ~ and 3 chains are a subset of the monocyte/macrophage lineage.
Enrichment of HLA-DRcr Protein in the Adherent
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HLA-DR rnRNA Expression in the Monocyte/Macrophage Lineage of One Patient Tested.
Here we investigated the origin of the HLA-DRB1 message of one patient's MNCs after separating the nonadherent cells from the adherent cell populations by multiple rounds of polystyrene adsorption. Total RNA was isolated from the various cell fractions and subjected to RT-PCR analysis. Our results show that the mRNA specific for HLA-DR31 was enriched in the adherent cell fraction as compared to the mRNA seen in the nonadherent cells, whereas EBV-B cells of the same patient lacked any detectable HLA-DIk31-specific mRNA (Fig. 6 a) .
To demonstrate that the HLA-DRBi-specific transcript seen in the adherent cell population originates from a monocyte/macrophage lineage, we investigated the expression pattern of the cytokines TNF-B and M-CSF in the same cell fractions. Whereas TNF-3 was constitutively produced by human EBV-B ceils, the cytokine M-CSF was dearly increased in adherence-activated macrophages. As shown in Fig. 6 b, no TNF-3 message, indicative of the presence of lymphoid cells, was found in the adherent cell fraction. However, mRNA encoding M-CSF could easily be detected (Fig. 6 c) . These findings indicate that the HLA-DK~1 gene expression observed in the MNCs of the patient is derived from cells of the monocyte/macrophage lineage. In addition, the majority of the activated cells within the antigen-stimulated MNC cultures expressed the TCR-od3 complex in the patients as well as in the controls (data not shown). Table  1 demonstrate that in contrast to healthy controls, the EBV-B cells from both patients were unable to induce antigenspecific stimulation of a normal, HLA-DK4-restricted (i.e., HLA-DR compatible to the patients). Tet Tox-specific T cell line, whereas the patients' EBV-B cells behaved normally with respect to accessory cell function for PWM-induced T cell proliferation. In addition, the EBV-B cells from one patient tested were unable to present antigen (Tet Tox) to autologous, long-term cultured, antigen-reactive T cells (data not shown). Table  2 show that MNCs from our patient responded to both allogeneic class I and II antigens, although alloresponse to M H C class I was lower than in the control (the patient's responder cells and the BCH-stimulator cells shared one class I determinant, HLA-A2). The patient's cellular response to M H C class II antigens could be inhibited by adding the mAb 9-49 to the system, known to block class II-specific alloresponses (19) . Addition of the M H C class I-specific mAb PA2.6 inhibited M H C class I-specific allostimulation, whereas it had no effect on M H C class II. brothers presented in this study was based on flow cytometric analysis ofMNCs. FACS | analysis of their EBV-B cells failed to detect MHC dass II antigens, whereas class I and Ii chain surface expression was comparable to the controls. Since the antibodies used recognize monomorphic dass II determinants, the observed lack of HLA-DR, -DQ, and -DP surface ex- Whereas IFN-T treatment could not restore class II ex- To examine B cell accessory cell function for antigen-and mitogen-induced T cell proliferation, a Tet Tox-specific normal T cell line (2.5 x 105/ml) was stimulated for 3 d with Tet Tox (10 LF/ml) or PWM (1:1,000) in the presence of autologous or HLA-DR-compatible EBV-B cells from control individuals or the patients (2.5 x 10S/ml). As a control, T cells were cocultured with EBV-B cells in medium alone. Antigen-or mitogen-induced T cell proliferation was determined by measuring [3H]thymidine incorporation and results are expressed as dpm [3H]thymidine uptake (mean + SD of triplicate cultures). pression in most BLS patients' B call lines (6, 9, 37, 38), IL-4 was able to enhance class II antigen expression on B and T cells of MHC class II-deficient CID patients (39, 40) . Though IFN-~ and IL-4 are strong inducers of class II genes in a variety of cells, neither cytokine was able to restore class II-specific mRNA levels in our patients' EBV-B cells (data not shown). Analysis of the transcription of HLA-D locus genes by RT-PCR revealed an uncoordinated expression of the class II isotype ol and fl chains in the EBV-B cells derived from the twin brothers. Whereas HLA-DRoe, -DQol, and -DP3 chain-specific transcripts were readily detected, no message was observed for HLA-DR3, -DQ3, or -DPoe. Only after extremely extended exposure time, was a faint signal for HLA-DQ~ observed. Importantly, gene expression of the Ii chain was normal or even increased in both patients' EBV-B cells. Furthermore, proteins for HLA-DRo~ and the Ii chain were present as visualized by immunoblotting of cell lysates, indicating that the observed transcripts were functional and that a translational defect could be ruled out. The uncoordinated expression of the class II isotype o~ and/~ chains detected differs from all other published results concerning regulation of HLA-D locus genes. Four levels of regulation have been characterized on the basis of the defects observed in MHC class II gene expression. Level one comprises cells from BLS patients responsive to cytokine treatment (3). The second level of gene regulation involves combined class II and Ii chain expression, as illustrated by defects in class II-negative mouse mutants (41) . A third level includes defective expression of all HLA-D locus genes, whereas expression of the Ii chain is not affected, as described for several MHC class II-negative patients (9), for the EBV-B cell lines BLS-2 and BCH (8, 12) , and for the laboratory mutants RJ2.2.5 and 6.1.6 (12, 1419 Hauber et al. 42 ). The fourth and last level concerns rare cases with dissociation in gene regulation of the class II isotypes. DePreval et al. (9) reported a class II-deficient, patient-derived B cell line expressing low amounts of HLA-DR oe and 3 chainspecific mRNA, whereas the other two isotypes were absent. This mRNA pattern (DRc~ +3 +, DQ-, DP-) distinguishes this B cell line from other class II-negative patients tested (9). Furthermore, a subclone of a human erythroleukemia cell line (HEL-DR +) expressing HLA-DR and -DP, but no -DQ mRNA, has been described (43) . In another BLS patient-derived B cell line (BLS-1) a very low level of HLA-DQol mRNA was present, whereas -DR, -DP, and -DOff transcripts were not detected (8) . Although the defect seen in our patients' EBV-B cells is closest to the fourth level with heterogeneous defects in gene regulation (DKee +3-, DQoe~fl -, DPol-fl+), their class II isotype mRNA pattern dearly distinguishes them from other members of that group, e.g., HEL-DR + cells (DRoe+3 + , DQ-, DPoe+), BLS-1 cells (DR-, DQol § DP-), and the laboratory mutant clone 13 (DR-, DQo~+3 +, DP-) (7, 8, 37) .
Patients' CD4 + T Cells Respond to Recall Antigen. Flow cytometric analysis of peripheral blood MNCs after antigenic stimulation was carried out to investigate whether the patients' T cells are capable of responding to recall antigen (Tet
Patients' EBV-B Cells Are Unable to Present Recall Antigen. The above described findings dearly demonstrate that CD4 § T cells become activated and express IL-2R after
Lympkocytes from One Patient Tested Mount an MHC Class I-
Fusion experiments between different class II-defective cell lines from BLS patients and laboratory mutant cell lines have shown that genetic defects in trans-activating factors can lead to a failure in transcription and expression of class II genes (3, 12) . Because of these fusion experiments, complementation groups were defined: most class II-negative patients' B cell lines (DR-, DQ-, DP-) and the BLS-1 cell line (described above) belong to complementation group I. Binding of a protein (KF-X) to the X box sequences on the HLADKoe promotor was deficient in the cells of this group I (44) . Whereas nearly all members (RJ2.2.5, BLS-2, BCH, etc.) of the complementation group II did not express any of the HLA-D locus genes, clone 13 was negative for DR and DP, but does express DQ. Benichou et al. (12) suggested that the cell lines of this group II lack the activity of a gene that can differentially regulate DR/DP and DQ promotors (12). Steimle et al. (45) identified a splicing mutation in a gene coding for a tram-activator protein (CIITA) necessary for MHC class II expression. CIITA is responsible for the class II regulatory defect in the cell lines of the patients and mutants belonging to complementation group II (38, 45) . The defects responsible for the complete lack of class II gene expression in cell lines belonging to complementation groups III (6.1.6) and IV (SJO and TF) are still unknown. The differential expression of ol and fl chains of the individual HLA-isotypes observed in our patients' EBV-B cells differs from all other B cell lines of class II-deficient patients and laboratory mutants described. The results clearly demonstrate an uncoordinated expression of HLA-D locus genes and reflect regulatory mechanisms unrecognized up to now. We therefore suggest the existence of a new level of regulation of the MHC class II molecules. It cannot be differentiated whether the regulatory mechanism is chain specific or represents a coordinated regulation of several chains, e.g., DR3, DQfl, and DPol. However, the results indicate that the B cells of our patients represent a new complementation group.
Whereas no message for DR3, DQ3, or DPcr could be observed in the patients' EBV-B cells, trace amounts of specific mRNA were found in their MNCs. Gene expression of DRoe, DQc~, and DPfl was normal in the MNCs as well. Quantification revealed that in one patient's MNCs (KER) 7-8% and in the other patient (KEN) 3-6% of the mRNAs encoding HLA-DR3, -DQ3, and -DPa were detectable. Moreover, the trace amounts of mRNA found in both patients' MNCs were confirmed by the detection of protein for HLA-DR.fl. These results indicate that regulation of the class II genes vary depending on the cell type.
Class II-expressing cells were further characterized by fractionating MNCs from one child (KEN) and his mother into nonadherent and adherent cells. We analyzed the expression of the HLA-D locus gene DRB found to be defective in the patients' EBV-B cells. Interestingly, HLA-DRB-specific mRNA could be detected in the adherent cell population in about half of the quantity (57%) expressed by cells of the mother. To further characterize these cells, we examined the expression pattern of certain cell-specific cytokines, e.g., TNF-3 and M-CSF. Whereas TNF-3 is predominantly a product of lymphocytes and constitutively produced by human EBV-B cell lines, M-CSF is strongly expressed by macrophages, especially after activation by adherence to plastic and during differentiation (46) . As expected, TNF-3 mRNA levels were high in EBV-B cells and in the nonadherent fraction, indicative of an enrichment of lymphoid cells. Whereas no transcripts for TNF-3 were detectable in the adherent cell fraction, the M-CSF mRNA level was increased, confirming enrichment of cells of the monocyte/macrophage lineage. These results indicate that HLA-DR-expressing cells are obviously cells of the monocyte/macrophage lineage present in the adherent cell fraction of the patients' MNCs. This finding supports the assumption of a "fine tuning" of the regulatory mechanisms of the MHC class II genes (3, 47) . 1420 MHC class II molecules play a key role in the regulation of antigen-induced immune responses due to their pivotal role in antigen presentation. Peptides bound to class II molecules on the surface of APC are the ligand for specific TCRs on CD4 + T cells (48) . In addition, class II expression on thymic epithelial cells is critical for the generation of mature CD4 + T cells (49) . The majority of previously described MHC class II-deficient patients showed a marked reduction in peripheral blood CD4 + T cell counts (50) . The CD4 lymphopenia was independent of the clinical status of the patients, and thus appeared to be in consequence of MHC class II deficiency (51). A similar reduction or complete absence of CD4 + T cells in the periphery has been found in MHC class II-deficient mice that lacked cell surface expression of class II molecules due to disruption of the class II gene in embryonic stem cells (52, 53) . Treatment of the mice with MHC class II-specific antibody in vivo prevented the differentiation of immature thymocytes into mature CD4 +, CDS-T cells (54) .
The two boys described here lacked MHC class II antigen on the surface of their peripheral blood leukocytes, but in contrast to previously described patients, presented with normal numbers of CD4 + T cells in the periphery (13, 50). Furthermore, specific antibodies were found after vaccination in vivo (13). In agreement with the patients' observed antibody response, the present study shows that CD3 + T cells became activated and expressed IL-2R (CD25) in response to stimulation of MNCs with recall antigen (Tet Tox). CD4 § TCR-o~/fl + cells were the major activated phenotype within these T cell populations.
The results seen on the transcriptional level in the two patients clearly indicated that regulation of MHC class II expression was different in nonadherent cells (e.g., B cells) compared to a subpopulation of cells observed in the adherent MNC fraction. Further investigations showed that the patients' B cells were also different from other APCs (e.g., monocytes, macrophages, dendritic cells) with respect to their capacity to present recall antigen, which is known to require functional MHC class II molecules. Whereas APCs present within the boys' MNC population were capable of inducing antigen-specific activation of CD4 + T cells, our patients' EBV-transformed B cells were unable to function as APCs in the activation of autologous antigen-reactive T cells or a normal, HLA-DR-compatible, antigen-specific T cell line derived from a healthy individual. The data show that cells contained within the MNCs other than B cells function as APCs in inducing recall antigen-specific T cell responses in the two boys. Supporting these data, a subpopulation of cells acting as APCs within the adherent MNC fraction, but not patients' B cells, expressed DRf-specific mRNA and DRc~ protein.
Although expression of MHC class II molecules on the surface of the patients' MNCs was not detected by flow cytometry, cells of the monocyte/macrophage lineage might still express very low levels of class II antigens on their surface, sufficient to stimulate antigen-reactive CD4 + T cells. In accordance with this hypothesis, it is known that expression of very low numbers of antigen/MHC class II complexes on an APC, probably as few as 200-300 complexes, are suificient to stimulate a T cell (55) .
In a previous study, we found that T cells from a patient with MHC class II deficiency were able to respond to class I alloantigens, but failed to recognize allogeneic MHC class II determinants. The lack of the MHC class II-specific T cell repertoire was accompanied by a substantially decreased number of circulating CD4 + lymphocytes (56) . Although this has not been examined directly, both fndings might have been due to defective expression of MHC class II antigen on thymic epithelial cells.
In contrast, T cells tested in one of the two patients described in the present paper could respond to MHC class I and II aUostimulation, and this response could be inhibited by mAbs of the respective specificity. Compared to the previously described patient by Mannhalter et al. (56) , the T cells of the patient examined in this study were capable of recognizing both MHC class I and II antigens. Whereas direct examination of MHC class II expression in the thymus of the two boys is not possible, a normal class II-specific T cell response might be due to a residual expression of class II antigens in the thymus, which also enabled the maturation of normal numbers of CD4 + T cells as present in our patient.
On the basis of the above considerations, it is tempting to speculate that B cells and monocytes/macrophages may acquire the capacity to regulate class II genes in a distinct fashion, pointing to cell type-specific factors involved in regulatory pathways of the class II molecules. In this sense, the biological role of MHC class II antigens should not only be seen within their structural characteristics, but also in the context of a developmentally controlled program of differentiation of various cell types. 
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